Education
About Us
Working with TipRanks
Follow Us
Cannara Biotech (TSE:LOVE)
:LOVE
LOVE Stock Chart & Stats
C$1.83
C$0.03(3.90%)
At close: 4:00 PM EST
C$1.83
C$0.03(3.90%)
Day’s Range― - ―
52-Week RangeC$1.06 - C$2.07
Previous CloseN/A
Volume7.64K
Average Volume (3M)45.69K
Market Cap
C$176.24M
Enterprise ValueC$193.62M
Total Cash (Recent Filing)C$16.52M
Total Debt (Recent Filing)C$34.85M
Price to Earnings (P/E)14.6
Beta0.36
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding95,782,150
10 Day Avg. Volume37,006
30 Day Avg. Volume45,690
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.64
Price to Sales (P/S)1.57
P/FCF Ratio12.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitability MarginsSustained high gross and operating margins indicate structural cost control and pricing power in cultivation and value-added products. Healthy margins support reinvestment in facilities, R&D and distribution, cushioning the business through regulatory or cyclical fluctuations over months.
Consistent Revenue ExpansionOngoing revenue growth across periods reflects market share gains and diversified product mix (cultivation, extraction, infused products). Durable top-line expansion supports scale economies, channel partnerships and long-term capacity utilization over the next several quarters.
Improving Leverage ProfileFalling leverage and rising equity reduce financial risk and increase strategic flexibility for capex, expansion or M&A. A healthier balance sheet lowers refinancing pressure and enhances resilience to margin or demand shocks over a multi-month horizon.
Bears Say
Declining And Volatile Free Cash FlowA drop and historical volatility in free cash flow undermines the firm's consistent ability to self-fund capex, repay debt or pursue strategic investments. This variability increases reliance on external financing and raises execution risk during adverse market moves.
Meaningful Absolute Debt LevelDespite improving leverage ratios, a material $34.9M debt load still creates fixed obligations that can constrain cash flow allocation. In a softening demand or margin scenario, servicing this debt could limit capital flexibility and slow strategic initiatives.
Earnings Normalization Vs Prior YearA decline from last year's higher profit level suggests demand or margin pressures and reduces retained earnings for reinvestment. Prolonged normalization could compress growth investments and elevate sensitivity to cost inflation or regulatory headwinds.
Cannara Biotech News
LOVE FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.06 and its highest was C$2.07 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$176.24M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Apr 29, 2026 which is in 64 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Jan 26, 2026. The company reported C$0.01 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.01.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Overvalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 95,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products through e-commerce platform. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
LOVE Company Deck
LOVE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record-breaking metrics and significant market share growth in key regions and product categories. However, there are challenges in maintaining market share in certain regions and managing cash flow effectively.View all TSE:LOVE earnings summariesTechnical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
Cannabist Company Holdings
―
Grown Rogue International
―
Options Prices
Currently, No data available
---